Poland· PL-100526072
Romvimza
A other protein kinase inhibitors product containing vimseltinib, registered in Poland by Deciphera Pharmaceuticals (Netherlands) B.V.. The same ATC class is registered in 2 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Vimseltinib is registered in 2 of 19 countries.
Countries holding a registration under ATC L01EX (other protein kinase inhibitors), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 1 of them publish a price we can compare per daily dose
Vimseltinib · ATC L01EX
2 / 19 countries
- Canada
- Polandprice
The record
At a glance
URPL (Poland)- Active substance
- Vimseltinib
- Manufacturer
- Deciphera Pharmaceuticals (Netherlands) B.V.
- Country
- Poland (PL)
- ATC code
- L01EX
- ATC class
- Other protein kinase inhibitors
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Vimseltinib in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesROMVIMZADeciphera Pharmaceuticals, LLC
- CzechiaROMVIMZADeciphera Pharmaceuticals (Netherlands) B.V., Amsterdam
- SpainROMVIMZA 30 MG CAPSULAS DURASDeciphera Pharmaceuticals (Netherlands) B.V.
- FinlandROMVIMZADeciphera Pharmaceuticals (Netherlands) B.V.
- FranceROMVIMZA 30 mg, géluleDECIPHERA PHARMACEUTICALS (NETHERLANDS) (PAYS-BAS)
- BelgiumRomvimza 30 mgDeciphera Pharmaceuticals (Netherlands)
- IcelandROMVIMZADeciphera Pharmaceuticals (Netherlands) B.V.
- NetherlandsROMVIMZA 30 mg harde capsulesDeciphera Pharmaceuticals (Netherlands) B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Romvimza
- Liechtenstein · Romvimza
- Norway · Romvimza
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/958cf20f-d637-4f51-92ba-83d0f91a046b GET /v1/drugs/958cf20f-d637-4f51-92ba-83d0f91a046b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Kapsułki twarde",
"source": "urpl",
"strength": "30 mg",
"packaging": "Rpz ¦ EU/1/25/1968/003 ¦ 164047\n8 kaps.",
"substance": "Vimseltinib 30 mg",
"common_name": "Vimseltinib",
"pl_product_id": "100526072",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about vimseltinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.